In vivo, administration of dimethylaminomicheliolide, a pro-drug of MCL, reduced unilateral ureteric obstruction–induced renal fibrosis that was associated with lesser pEMT and a reduction in IL-11–related pathologies. This evidence concerns the gene IL11 and Ureteral obstruction.